Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2023 call → NOWe need to determine if management explains where the company's business is going by narrating what its counterparties are themselves doing and scaling. The key is whether management's forward account is substantially about the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, etc., that the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories. Let's analyze the transcript. The company is MannKind, which has multiple products: Afrezza (diabetes), Tyvaso DPI (for PAH/PH-ILD) in collaboration with United Therapeutics, and pipeline products like MNKD-101 (clofazimine for NTM) and MNKD-201 (nintedanib for IPF). The call covers Q4 2023. Management discusses Tyvaso DPI extensively. They mention record revenue, record production, and the royalty sale. They talk about United Therapeutics' trials (TETON 1 and TETON 2) being 70% enrolled. They also mention the high-speed fill finish line qualification. They talk about the growth of Tyvaso DPI and how it's ahead of expectations. They also discuss the competitive landscape and how they are making as much as they can. But the question is specifically about whether management explains the company's forward business by narrating what counterparties are doing and scaling. For Tyvaso DPI, the counterparty is United Therapeutics (UT). Management does talk about UT's trials and the product's growth. However, is that the primary driver of the forward account? They also talk about their own pipeline, Afrezza, etc. Let's look for specific instances where management describes the counterparty's own trajectory as the reason for the company's coming volume. For example, they mention that UT's TETON trials are 70% enrolled, and once they finish enrollment, they'll have 12 months there, so we should expect data. That is about UT's program. But does that directly drive MannKind's revenue? Yes, because MannKind manufactures Tyvaso DPI for UT. So if UT's trials expand, that could lead to more patients and more demand. But the trials are for new indications? Actually, TETON 1 and TETON 2 are for PH-ILD? They are already approved for PH-ILD? Actually, Tyvaso DPI is approved for PAH and PH-ILD.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.